Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.
Down 31% pre-market, but all the headlines from the last 24 hours are positive... The stock has been halted. Trevena's painkiller succeeds in two late-stage studies Source: http://www.reuters.com/article/us-trevena-study-idUSKBN1601DQ Trevena Makes Case for Better Post-Surgical Opioid with New Study Data Source: https://www.thestreet.com/story/140...post-surgical-opioid-with-new-study-data.html Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain Source: https://globenewswire.com/news-rele...eridine-in-Moderate-to-Severe-Acute-Pain.html Trevena (TRVN) Halted, News Pending Source: http://www.streetinsider.com/Trading+Halts/Trevena+(TRVN)+Halted,+News+Pending/12570103.html
I didn't do more than 5 minutes of research, but every article in the last 24 hours was positive... I don't get it
